jRCTs062180038CompletedNot Applicable
Usefulness of linked color image (LCI) for colon SSA/P surveillance (LCI for SSA/P)
Not provided0 sites51 target enrollmentStarted: May 7, 2019Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 51
- Primary Endpoint
- -
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized Controlled Trial
- Intervention Model
- Crossover Assignment
- Primary Purpose
- Diagnostic Purpose
- Masking
- Open(masking Not Used)
Eligibility Criteria
- Ages
- 20age old over to No limit (—)
- Sex
- All
Inclusion Criteria
- •Patients with SSA/P
Exclusion Criteria
- •Patients who underwent colectomy, Antiplatelet medicine
Outcomes
Primary Outcomes
-
Detection rate of SSA/P
Secondary Outcomes
No secondary outcomes reported
Investigators
Similar Trials
Recruiting
Not Applicable
MSS (MSS)Male infertilityjRCT104024010230
Recruiting
Not Applicable
MSSP RCT (MSSP RCT )irreversible pulpitis
pulp necrosis
Apical periodontitisjRCTs052240103384
Active, not recruiting
Phase 1
A Phase 1 Study of SGN-ALPV in Advanced Solid Tumorsgastroesophageal junction [GEJ] carcinoma, Non-small cell lung cancer (NSCLC), Gastric cancer, Cervical cancer, Ovarian cancer, Endometrial cancer, Malignant ovarian GCT with the exception of pure teratomas, Malignant testicular germ cell tumor (GCT) with the exception of pure teratomas, Gastroesophageal junction carcinoma, Malignant extragonadal GCT with the exception of pure teratomas or tumors with primaries arising from the central nervous system (CNS)MedDRA version: 21.1Level: LLTClassification code: 10043338Term: Testicular malignant germ cell tumor NOS Class: 10029104MedDRA version: 21.1Level: PTClassification code: 10017758Term: Gastric cancer Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864MedDRA version: 20.0Level: HLTClassification code: 10033222Term: Ovarian germ cell neoplasms malignant Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10008229Term: Cervical cancer Class: 10029104MedDRA version: 21.0Level: PTClassification code: 10014733Term: Endometrial cancer Class: 100000004864MedDRA version: 21.1Level: LLTClassification code: 10066354Term: Adenocarcinoma of the gastroesophageal junction Class: 10029104MedDRA version: 20.0Level: PTClassification code: 10033128Term: Ovarian cancer Class: 100000004864MedDRA version: 20.0Level: LLTClassification code: 10073060Term: Extragonadal primary germ cell tumor Class: 10029104CTIS2022-500094-14-00Seagen Inc.254
Active, not recruiting
Phase 1
A clinical study to test the safety (any good or bad effects) of CC-90011 in combination with standard of care (cisplatin and etoposide), on how long the drug can stay in the body and if it can control the disease of people diagnosed with extensive small cell lung cancer and have not had any previous treatment for the disease. CC-90011, single agent, will be also given in consolidation after completion of the 4 to 6 cycles of chemotherapyextensive stage small cell lung cancerMedDRA version: 21.1Level: PTClassification code: 10041068Term: Small cell lung cancer extensive stage Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10041067Term: Small cell lung cancer Class: 100000004864CTIS2023-509800-14-00Celgene Corp.66
Active, not recruiting
Phase 1
Study of safety, tolerability, pharmacokinetics and pharmacodynamics of MSD-001 in healthy participantsMental health disordersCTIS2024-512939-67-00Mindstate Design Labs Inc.68